Chlorambucil-associated pneumonitis.
A patient developed an interstitial pneumonitis while receiving chlorambucil for a chronic lymphocytic leukemia (cumulative dose, 8,340 mg). Withdrawal of drug treatment was followed by rapid improvement in the clinical condition. Bronchoalveolar lavage showed a T-lymphocytic alveolitis, whereas blood lymphocytes were predominantly of the B phenotype. The T-lymphocytic alveolitis persisted 6 weeks after drug therapy cessation with a predominant CD8+ phenotype, as observed in some hypersensitivity pneumonitis induced by drugs.
Crestani
B
B
Immuno-Hematology Unit, Hôpital Saint Louis, Paris, France.
Jaccard
A
A
Israël-Biet
D
D
Couderc
L J
LJ
Frija
J
J
Clauvel
J P
JP
D000542:Alveolitis, Extrinsic Allergic / Q000139:chemically induced* / Q000473:pathology; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology; D002699:Chlorambucil / Q000009:adverse effects*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000473:pathology; D008218:Lymphocytosis / Q000473:pathology; D008297:Male; D008875:Middle Aged; D013601:T-Lymphocytes / Q000473:pathology; D050378:T-Lymphocytes, Regulatory / Q000473:pathology
D002699:Chlorambucil